Chunmou Li^*1, Xiaomin Peng^*1, Chuchu Feng^*1, Xilin Xiong^*, Jianxin Li^†, Ning Liao^‡, Zhen Yang^§, Aiguo Liu^¶, Pingping Wu^*, Xuehong Liang^†, Yunyan He^‡, Xin Tian^§, Yunbi Lin^§, Songmi Wang^¶, Yang Li^*

Oncology Research, Vol.28, No.7-8, pp. 791-800, 2020, DOI:10.3727/096504021X16184815905096

Abstract This nonrandomized, multicenter cohort, open-label clinical trial evaluated the efficacy and safety of combined chemotherapy with arsenic trioxide (ATO) in children with stage 4/M neuroblastoma (NB). We enrolled patients who were newly diagnosed with NB and assessed as stage 4/M and received either traditional chemotherapy or ATO combined with chemotherapy according to their own wishes. Twenty-two patients were enrolled in the trial group (ATO combined with chemotherapy), and 13 patients were enrolled in the control group (traditional chemotherapy). Objective response rate (ORR) at 4 weeks after completing induction chemotherapy was defined as the main outcome,… More >

Shu Chen^*, Lianhua Jin^†, Shu Nie^†, Lizhi Han^†, Na Lu^†, Yan Zhou^†

Oncology Research, Vol.26, No.3, pp. 445-455, 2018, DOI:10.3727/096504017X14974834436195

Abstract Accumulating evidence indicates that microRNA-205 (miR-205) is involved in tumor initiation, development, and metastasis in various cancers. However, its functions in neuroblastoma (NB) remain largely unclear. Here we found that miR-205 was significantly downregulated in human NB tissue samples and cell lines. miR-205 expression was lower in poorly differentiated NB tissues and those of advanced International Neuroblastoma Staging System stage. In addition, restoration of miR-205 in NB cells suppressed proliferation, migration, and invasion and induced cell apoptosis in vitro, as well as impaired tumor growth in vivo. cAMP-responsive elementbinding protein 1 (CREB1) was identified as a More >